Lung clearance index and steroid response in pediatric severe asthma

Samantha Irving1,2, Louise Fleming1,2, Fatima Ahmad2

  • 1Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Pediatric Pulmonology
|February 7, 2020
PubMed

Insights

Lung clearance index (LCI) is elevated in children with severe therapy-resistant asthma (STRA). LCI improved with parenteral steroids, suggesting it may help assess steroid response in pediatric asthma.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Asthma Research

Background:

  • Lung clearance index (LCI) is a sensitive measure of airway disease.
  • Abnormal LCI is observed in asthma, particularly in severe, difficult-to-treat cases.
  • Severe therapy-resistant asthma (STRA) presents unique challenges in pediatric management.

Purpose of the Study:

  • To investigate LCI differences between children with STRA, difficult asthma (DA), and healthy controls.
  • To assess the impact of parenteral steroids on LCI in children with STRA.
  • To evaluate LCI as a potential biomarker for steroid response in pediatric asthma.

Main Methods:

  • Sixty-four children with high-dose asthma (GINA steps 4/5) underwent LCI and spirometry.
  • Forty-three had STRA and 21 had DA.
  • LCI, spirometry, and FeNO were measured before and 4 weeks after intramuscular triamcinolone in STRA patients.

Main Results:

  • LCI was significantly more abnormal in STRA patients compared to DA and healthy controls.
  • LCI improved in 13 of 20 STRA patients with abnormal baseline LCI following parenteral steroid administration.
  • Improvements in LCI and fractional exhaled nitric oxide (FeNO) were concordant.

Conclusions:

  • A subset of children with STRA exhibits elevated LCI that responds to parenteral steroids.
  • LCI shows potential as an additional tool for assessing steroid efficacy in pediatric asthma.
  • LCI may offer valuable insights into airway disease and treatment response in severe pediatric asthma.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
669
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K